A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

Sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Study ID
NCT07734311
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Ecnoglutide Injection — DRUG
    subcutaneous injection
  • placebo with matching volume — DRUG
    subcutaneous injection

Study Details

The main purpose of the study is to evaluate the efficacy and safety of ecnoglutide injections versus placebo in obese participants with KOA.

Key Dates

First listed
Jul 29, 2026
Start date
Aug 3, 2026
Status verified
May 2026
Primary completion
May 31, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
360 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Ecnoglutide Injection
    Once weekly
  • Placebo Comparator: Placebo
    Once weekly

Primary Outcome Measure

Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score [ Time Frame: Baseline, week 68 ]

Central Contacts

Find similar trials

Nationwide
Osteoarthritis (other) trialsObesity / overweight trialsOrthopedics trialsMusculoskeletal disorders trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies